Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation.

Over the past two years, Merck (NYSE: MRK) has faced several challenges, resulting in a decline in the company's share price.

Merck & Co. has won European Commission approval of a formulation of its blockbuster cancer drug Keytruda that can be injected under the skin. The Rahway, N.J., drugmaker on Wednesday said the green ...

Libtayo plus chemotherapy is potentially more cost-effective than Keytruda plus chemotherapy for advanced NSCLC, offering lower costs and higher QALYs. The study's model, based on clinical trial data, ...

Jazz Pharmaceuticals and Zymeworks announced positive topline phase 3 results for Ziihera in HER2-positive GEA. Click here to ...

Dear reader, when we discuss the best-selling medications of all time, we’re exploring more than just products with massive sales; we’re highlighting milestones in the ...

The experts agreed that perioperative approaches in muscle-invasive bladder cancer continue to evolve. Ongoing data will ...

Pharma companies are spending billions on a treatment based off old drugs, with little evidence it will extend lives.

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer clinical study utilizing ...

HCW11-040 expands and activates human peripheral blood lymphocytes (PBMCs) and memory T cells significantly better than pembrolizumab alone. HCW11-040 exhibits significantly better anti-tumor activity ...

Additional updates from the ongoing Phase 1b/2 trial with muzastotug, previously reported at ASCO 2025, are anticipated in the coming months SAN DIEGO and SUZHOU, China, Oct. 31, 2025 (GLOBE NEWSWIRE) ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Merck, which has claimed ...